Detalles de la búsqueda
1.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Lancet Oncol
; 24(7): 744-756, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37329891
2.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
; 382(25): 2419-2430, 2020 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469182
3.
Differential AMP-activated Protein Kinase (AMPK) Recognition Mechanism of Ca2+/Calmodulin-dependent Protein Kinase Kinase Isoforms.
J Biol Chem
; 291(26): 13802-8, 2016 Jun 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-27151216
4.
Use of Real-World Evidence in a Virtual Bridging Analysis for a Human Epidermal Growth Factor Receptor 2-Targeted Antibody-Drug Conjugate in Gastric Cancer.
J Clin Pharmacol
; 63(11): 1244-1255, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37377133
5.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
J Clin Oncol
; 41(4): 816-825, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36379002
6.
The use of cationic nanogels to deliver proteins to myeloma cells and primary T lymphocytes that poorly express heparan sulfate.
Biomaterials
; 32(25): 5900-5, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21605901
Resultados
1 -
6
de 6
1
Próxima >
>>